Concerns mounting over delayed review of 576 bioequivalence drugs

Published: 2008-06-26 06:58:00

Updated: 2008-06-26 06:58:00

Despite the Korea Food and Drug Administration’ pledge that it will complete the reassessment of 576 drugs by 2010, there are growing worries over the KFDA’s slow process.

Sources say that of the 576 items whose bioequivalence has yet to be proven, the KFDA has still failed to re-evaluate 141 ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK